<DOC>
	<DOCNO>NCT02513381</DOCNO>
	<brief_summary>This double blind randomise placebo-controlled study involve woman polycystic ovary syndrome ( PCOS ) . The patient randomise either Vitamin D 3200 IU placebo three month . The main hypothesis study `` Vitamin D improve hormonal , metabolic cardiovascular risk marker woman PCOS '' .</brief_summary>
	<brief_title>Effect Vitamin D Hormonal , Metabolic Cardiovascular Risk Factors Patients With Polycystic Ovary Syndrome</brief_title>
	<detailed_description>Polycystic ovary syndrome ( PCOS ) common condition woman could present irregular period , excessive hair growth body , acne cyst ovary . PCOS also associate increased risk problem later life like diabetes , high cholesterol level heart disease . One risk factor increase incidence problem PCOS patient could low vitamin D level many woman polycystic ovary syndrome ( PCOS ) vitamin D deficient . Vitamin D supplementation may beneficial effect insulin level fat around abdomen . It see previous research study low level vitamin D relate great risk diabetes heart disease . Low vitamin D level also associate fat liver . The amount fat liver sign early liver disease . So , study investigator want supplement woman PCOS vitamin D deficiency vitamin D ( 3,200 IU ) examine effect hormone relate PCOS risk factor diabetes heart disease .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . Caucasian woman , age 1845 year , confirm diagnosis PCOS base three diagnostic criterion Rotterdam consensus [ 21 ] . 2 . Irregular period raise FAI 3 . Vitamin D &lt; 50 nmol/L . 1 . Nonclassical 21hydroxylase deficiency , hyperprolactinaemia , Cushing 's disease androgensecreting tumour exclude appropriate test clinically indicate . 2 . Any concurrent illness include type 2 diabetes , subject medication ( include medication interfere calceotrophic hormone ) precede 6 month . 3 . Women plan conceive . 4 . Women use oral implantable contraceptive treatment likely affect ovarian function , insulin sensitivity lipid least 3 month enter study . Stable dose metformin 3 month allow . Subjects advise use barrier contraception study period . 5. eGFR &lt; 60 . 6 . Hypersensitivity vitamin D excipients product . 7 . Peanut soya allergy . 8 . Nephrolithiasis . 9 . Diseases condition result hypercalcaemia and/or hypercalciuria .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>